Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Genzyme

This article was originally published in The Gray Sheet

Executive Summary

Genzyme: Offers $93 mil. in shares of Genzyme General Division common stock to acquire the assets of Genzyme Development Partners, L.P., also called the Surgical Aids Partnership. Genzyme established the Partnership in 1989 when it raised $36.8 mil. to fund development of surgical products to prevent postoperative adhesions. Premarket approval applications for the first of such products -- Seprafilm and Sepracoat -- are pending at FDA, and the company recently received the CE mark for Seprafilm. The stock offer "is in lieu of Genzyme's existing option," which stipulates that the surgical aids products business operate as a joint venture for two years following a product approval, after which Genzyme has an option to take over the partnership's interests in exchange for a $26 mil. lump-sum cash payment and 10% royalty payments for 10 years. The offer stipulates that shares be valued based on average closing price of Genzyme General Division stock "for the 20 trading days immediately preceding the fifth trading day prior to closing of the acquisition, provided that the average closing price is at least $60.99 and not more than $82.51," Genzyme says

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts